Pfizer Inc. (NYSE:PFE) Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,068,609 shares of the biopharmaceutical company's stock after selling 211,933 shares during the quarter. Epoch Investment Partners Inc.'s holdings in Pfizer were worth $54,880,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Passumpsic Savings Bank grew its stake in Pfizer by 8.4% in the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock valued at $743,000 after acquiring an additional 1,998 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Pfizer in the third quarter valued at approximately $1,499,000. Westside Investment Management Inc. increased its stake in shares of Pfizer by 7.7% during the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after purchasing an additional 1,004 shares in the last quarter. Diamant Asset Management Inc. raised its position in shares of Pfizer by 8.4% during the 3rd quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock worth $246,000 after purchasing an additional 660 shares during the last quarter. Finally, Morse Asset Management Inc purchased a new stake in Pfizer in the 3rd quarter valued at approximately $2,649,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group lowered their price target on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company's stock.

Pfizer Trading Down 0.3 %

Pfizer stock traded down $0.07 during midday trading on Monday, reaching $22.07. The stock had a trading volume of 31,814,050 shares, compared to its average volume of 40,452,372. The stock's 50-day simple moving average is $24.81 and its 200 day simple moving average is $26.11. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $125.17 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the business earned $0.10 EPS. The company's revenue for the quarter was up 24.7% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.